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Abstract
Metastasis is the primary cause of death in patients with breast cancer. Overexpression of c-myc in
humans correlates with metastases, but transgenic mice only show low rates of micrometastases. We
have generated transgenic mice that overexpress both c-myc and vascular endothelial growth factor
(VEGF) (Myc/VEGF) in the mammary gland, which develop high rates of pulmonary
macrometastases. Gene expression profiling revealed a set of deregulated genes in Myc/VEGF
tumors compared to Myc tumors associated with the increased metastatic phenotype. Cross-
comparisons between this set of genes with a human breast cancer lung metastasis gene signature
identified five common targets: tenascin-C (TNC), matrix metalloprotease-2, collagen-6-A1,
mannosidase-α-1A and HLA-DPA1. Signaling blockade or knockdown of TNC in MDA-MB-435
cells resulted in a significant impairment of cell migration and anchorage-independent cell
proliferation. Mice injected with clonal MDA-MB-435 cells with reduced expression of TNC
demonstrated a significant decrease (P < 0.05) in (1) primary tumor growth; (2) tumor relapse after
surgical removal of the primary tumor and (3) incidence of lung metastasis. Our results demonstrate
that VEGF induces complex alterations in tissue architecture and gene expression. The TNC signaling
pathway plays an important role in mammary tumor growth and metastases, suggesting that TNC
may be a relevant target for therapy against metastatic breast cancer.
© 2008 Nature Publishing Group All rights reserved
Correspondence: Dr MD Johnson, Lombardi Cancer Center, Georgetown University, The Research Building, W325, 3970 Reservoir
Rd., NW, Washington, DC 20057, USA. E-mail: E-mail: Johnsom@georgetown.edu or Dr JE Green, Dr Laboratory of Cancer Biology
and Genetics, National Cancer Institute, NIH, Building 37, Room 4054, 37 Convent Drive, Bethesda, MD 20892, USA. E-mail: E-mail:
jegreen@nih.gov.
7These authors contributed equally to this work.
8This paper is dedicated to the memory of Dr Robert Dickson.
9Contributed equally as senior authors.
NIH Public Access
Author Manuscript
Oncogene. Author manuscript; available in PMC 2009 September 11.
Published in final edited form as:
Oncogene. 2008 September 11; 27(40): 5373–5384. doi:10.1038/onc.2008.155.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Keywords
metastasis; vascular endothelial growth factor; transgenic mice; mammary cancer; tenascin-C
Introduction
Metastasis is the primary cause of mortality from breast cancer (BC), resulting in over 40 000
deaths per year in the United States (Jemal et al., 2007). A general lack of knowledge about
the molecular mechanisms involved in the metastatic process has greatly hampered the
development of therapies against this form of advanced disease. Therefore, a major challenge
remains to identify genes responsible for the acquisition of the metastatic phenotype, with the
ultimate goal of inhibiting the metastatic disease.
Multiple steps are involved in the metastatic process including angiogenesis, invasiveness,
migration through the extracellular matrix and stroma, intravasation into blood or lymphatic
vessels, and extravasation and growth of new tumor masses (Folkman, 2002; Gupta and
Massague, 2006). Invasion and tumor vascularization imply degradation of connective tissue,
a process that requires the activity of extracellular matrix (ECM) proteases, such as matrix
metalloproteases (MMPs) and serine proteases (Noel et al., 2004).
Many studies have shown that vascular endothelial growth factor (VEGF) is a key
proangiogenic factor that is overexpressed in virtually all solid tumors, acting through its
receptors VEGFR1 (Flt-1) and VEGFR2 (Flk-1/KDR). VEGF is overexpressed in BC, and a
strong correlation between VEGF expression and microvessel density has been demonstrated
(De Paola et al., 2002). VEGF plasma levels also correlate with presence of metastasis in
patients with BC (Adams et al., 2000). In addition, we and others have demonstrated that VEGF
may have a direct autocrine effect on tumor cells (Huh et al., 2005; Schoeffner et al., 2005),
suggesting that VEGF may stimulate tumor growth and metastases through nonvascular
mechanisms.
Amplification and overexpression of c-myc is frequently found in human BC and is associated
with metastasis to the lymph nodes and lungs (Deming et al., 2000). However, the MMTV-
Myc (Myc) mouse mammary tumor model is poorly metastatic (Amundadottir et al., 1995;
Hundley et al., 1997). Therefore, the fact that these transgenic animals are unable to fully mimic
the metastatic progression of human c-myc-associated breast tumor metastasis suggests that
c-myc may act in concert with other factors to produce the metastatic phenotype.
Considering the potentially important role of VEGF in BC metastasis, and that Myc mammary
tumors are poorly vascularized (Amundadottir et al., 1995), we hypothesized that targeting
VEGF expression to the mammary epithelium of Myc transgenic mice would promote a
metastatic phenotype. To test this hypothesis, we have generated compound transgenic mice
where both VEGF and c-myc are co-overexpressed in the mammary gland, and demonstrate
that these mice develop a high rate of lung macrometastases. Gene expression profiling of these
primary tumors indicates that the overexpression of VEGF results in the robust induction of
genes involved in angiogenesis, ECM proteins and processing enzymes, several of which have
been implicated in human metastatic disease. Functional analysis demonstrates that one such
gene, tenascin-C (TNC), is involved in the acquisition of the metastatic phenotype.
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Results
Myc/VEGF transgenic mice develop highly angiogenic and metastatic mammary tumors
The individual phenotypes of MMTV-Myc (Amundadottir et al., 1995; Hundley et al., 1997)
and MMTV-VEGF (Schoeffner et al., 2005) transgenic mice have been previously reported.
Although Myc female mice develop mammary tumors, the mammary glands of MMTV-VEGF
female mice appear morphologically similar to wild types and do not develop tumors
(Schoeffner et al., 2005).
Virgin Myc/VEGF transgenic females developed mammary tumors with a lower incidence
than Myc mice: 27% (13 of 48) vs 67% (36 of 54), possibly related to reduced levels of Myc
expression in Myc/VEGF tumors compared to Myc tumors (see below). Tumor onset was also
delayed in Myc/VEGF mice (76.1 ± 29 weeks) compared to Myc mice (37.3 ± 9), though tumor
multiplicity was similar between both genotypes (1.7 tumors per mouse, on average). All Myc
tumors were adenocarcinomas with a tubulopapillary pattern (Figure 1a), as previously
described (Amundadottir et al., 1995). However, Myc/VEGF tumors were pleomorphic
adenocarcinomas (Figure 1b), and some tumors exhibited an adenosquamous appearance
(Figure 1c). In addition, Myc/VEGF tumors demonstrated a general increase in fibrosis and
ECM content compared to Myc tumors. Mammary tumors arising in either Myc or Myc/VEGF
mice were characterized by the presence of appropriate transgene-specific transcripts
(Supplementary Figure 1).
Real time RT-PCR of angiogenic markers (Supplementary Table 1) revealed that VEGF was
increased 2.5-fold (P < 0.01) in Myc/VEGF tumors compared to Myc tumors. VEGFR1 (Flt-1)
and VEGFR2 (Flk-1) were also significantly increased (P = 0.001). CD-31 and vascular
endothelial Cadherin (VE-cadherin), specific markers for endothelial cells, were significantly
higher (P = 0.015 and P = 0.036, respectively) in Myc/VEGF tumors than in Myc tumors
(Supplementary Table 1). Quantification of vascular density by immunostaining for CD-31
(Figures 1e and f) demonstrated that Myc/VEGF tumors had increased vascularity compared
to Myc tumors. The mean vascular density (MVD) was 3.71 ± 1 (percent of total tumor) for
Myc tumors vs 16.8 ± 1 for Myc/VEGF tumors (P < 0.0004) (Figure 1g).
Lungs from a subset of mice that developed tumors were evaluated for metastases by detailed
histological analyses (Supplementary Table 2). Microscopic metastases were observed in 7 of
19 (36.9%) of Myc mice, with only 2 of 19 (10.5%) of mice developing macroscopic
metastases. Overall, 8 of 19 (42.1%) had metastases of any size. In contrast, 16 of 18 (88.8%)
of Myc/VEGF mice developed microscopic metastases and 8 of 18 (44%) of Myc/VEGF mice
developed macroscopic metastases. Overall, 16 of 18 (88.9%) had metastases of any size. Thus,
Myc/VEGF mice were more than twice as likely as Myc mice to develop lung metastases of
any size, and four times as likely to develop macroscopic metastases. In cross-sectional areas,
the size of Myc/VEGF lung metastases was more than 20 times larger (on average) than those
of Myc metastases (Supplementary Table 2).
To further investigate metastatic potential, 1 mm3 pieces of either Myc or Myc/VEGF tumors
were implanted subcutaneously into the flanks of female mice. All tumor implants grew
following transplant and the resultant Myc and Myc/VEGF tumors grew at approximately the
same rate. Eighty percent (8 of 10) of the Myc/VEGF transplant recipients (in both nude and
FVB/N background) developed macroscopic pulmonary metastases over a 3 to 4-week period.
In contrast, no macroscopic lung metastases were observed for transplanted Myc tumors (0 of
10).
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Genetic portraits of Myc/VEGF metastatic primary tumors reveal numerous changes in genes
related to ECM remodeling, invasion and adhesion
High-throughput gene expression profiles of Myc tumors were compared to those of Myc/
VEGF tumors, and 722 genes with a twofold differential expression (P < 0.01) were identified
(506 corresponding to upregulated genes and 216 to downregulated genes). Expression changes
in all five Myc/VEGF tumors were similar with a correlation coefficient of 0.71 and similar
patterns of expression. A selected list of genes with particular relevance to the acquisition of
the metastatic phenotype is presented in Table 1.
Examples of genes highly upregulated in primary tumors with high metastatic propensity were
fibronectin-1 and glycosylation-dependent cell adhesion molecule-1 (GLYCAM-1), whose
expression was increased by 6.8 ± 1.4- and 15.8 ± 2.7-fold, respectively (Figures 2a and b).
An example of a downregulated gene in tumors from mice overexpressing both Myc and
VEGF was cell adhesion molecule-2 (CEACAM-2) (Figure 2c). TNC mRNA was found to be
upregulated 5.5 ± 2.3-fold in Myc/VEGF tumors as compared to Myc tumor and confirmed by
western blot and immunohistochemistry (Figures 2d–f). Immunostaining was mainly found in
the ECM and, in a lesser extent, in tumor cells. The stromal compartment of the blood vessel
walls was also labeled, but not the endothelial cells. Myc/VEGF tumors exhibited a stronger
pattern of TNC staining (Figures 2e and f). Laminin-5-γ-2, a gene whose expression has been
linked to BC metastasis (Pyke et al., 1994), was upregulated by 10.6 ± 1.1-fold in tumors
overexpressing both Myc and VEGF. Immunostaining for laminin-5 was observed in tumor
cells and the ECM, and Myc/VEGF tumors showed more intense staining (Figures 2g and h).
The VEGF-dependent metastatic phenotype was characterized by numerous changes in the
expression of ECM proteins including collagens, ECM proteases and cell adhesion proteins
(Table 1). Of particular interest are type 1 collagen α-1 (Colla1), fibronectin-1 and tenascin-
C, as these genes have been identified in other microarray metastatic signatures (Ramaswamy
et al., 2003;Minn et al., 2005). The critical role of proteases in modifying the ECM and
promoting cell tumor invasion and metastasis has been well established (Stamenkovic, 2000).
Upregulation of numerous proteases in Myc/VEGF tumors was observed (Table 1), including
MMPs-2 and -23; cathepsins (-L and -C); cystatins (-B and -C), and disintegrin and
metalloproteinases (ADAMs)-8, -9, -12 and -19. We also identified deregulated expression of
genes belonging to the Rho GTPase signaling pathway in the tumors with high metastatic
propensity, including Rho-C, Rac-1, Rap and Pak-1 (Table 1) that follow a concordant pattern
of expression with reports of metastatic tumors published elsewhere (Schmitz et al., 2000).
Therefore, VEGF over-expression strongly modifies the tumor ECM, which likely elicits cell
migration and invasion of the primary tumor.
A significant reduction in c-Myc (−10.0 ± 0.1) expression was observed in the Myc/VEGF
transgenic tumors compared to Myc tumors (Table 1) and confirmed by western blot
(Supplementary Figure 2). Reduction in c-Myc levels might explain why Myc/VEGF mice have
a lower incidence and delayed onset of mammary tumors compared to Myc transgenic mice.
Microarray data generated for this study are available at http://www.ncbi.nlm.nih.gov/geo/.
Comparisons of mouse and human breast cancer lung metastasis signatures
In order to identify a set of candidate genes with a potentially high likelihood for influencing
the metastatic phenotype, we employed a cross-species comparison of gene expression profiles
identified in this study with array data from human mammary tumors implicated in lung
metastasis using a publicly available microarray data from metastatic BC patients retrieved
from GEO (GSE2603)
http://www.ncbi.nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE2603. A set of 54 genes,
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corresponding to a BC lung metastatic signature was cross-compared with the set of mouse
genes identified in this study. Five genes with a similar pattern of expression in both species
were identified: upregulated genes TNC, MMP-2, collagen-6-A1, mannosidase-α-1A, and the
downregulated gene HLA-DPA1. The functional role of TNC in BC lung metastasis was further
investigated as it has been implicated in tumor cell invasion (Tsunoda et al., 2003) and
remodeling of angiogenic tissues (Zagzag and Capo, 2002).
Tenascin-C blockade decreases migration of metastatic mammary cells
The cell line MV630, established from Myc/VEGF mammary tumors, expresses high levels
of VEGF, Flt-1, Flk-1 and TNC (data not shown). Anti-TNC blocking antibodies significantly
(P < 0.01) inhibited cell migration of MV630 cells (Figures 3a and b). A control IgG antibody
did not inhibit migration (result not shown). Although blockade of Flt-1 did not inhibit MV630
cell migration, blockade of Flk-1 signaling or the combination of anti-TNC blocking antibody
and the Flk-1 inhibitor resulted in a significant reduction in cell migration (P < 0.01) (Figures
3a and b). Flk-1 blockade caused inhibition of MV630 cell growth as well, as demonstrated
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (data not
shown). MDA-MB-435 cells, a human metastatic cancer cell line that constitutively expresses
TNC (Figure 3d), was used for knockdown experiments using a retroviral vector expressing
shRNA to TNC (Figure 3d). TNC expression was reduced by 90–93% in the clone shTNC-1
and 83.3% in the shTNC-3 with respect to shCtrl. Migration experiments were performed using
either parental cells, the control clone shCtrl, or shTNC-1 and shTNC-3 clones. Migration
assays further confirmed that downregulation of TNC causes a significant reduction (P < 0.05)
in the ability of MDA-MB-435 cells to migrate (Figure 3c). These results demonstrate that
tumor cell migration can be decreased by targeting TNC- and Flk-1-dependent signaling
pathways.
Interestingly, VEGF did not directly regulate the expression of TNC in tumor cells. Neither
the addition of exogenous VEGF nor the reduction of VEGF expression through the addition
of siRNA for VEGF altered the level of TNC in MDA-MB-435 cells (results not shown). This
result suggests that overexpression of VEGF does not directly increase TNC levels in tumor
cells, but likely acts through indirect mechanisms involving the stromal compartment.
Downregulation of TNC results in a significant decrease in mammary tumor growth, tumor
relapse and lung metastases
In vivo experiments were performed to determine the impact of TNC downregulation on tumor
growth and lung metastasis development. Female nude mice were injected with either 106
MDA-MB-435 parental cells, or shCtrl, shTNC-1 and shTNC-3 cell clones, into the mammary
fat pads (Figure 4a). Average tumor volume in MDA-MB-435 and shCtrl groups was similar,
whereas a significant decrease in tumor volume (approximately 50% reduction, P < 0.05) was
observed for both the shTNC-1 and shTNC-3 clones. Primary tumors were surgically removed
when they reached 1.5 cm in diameter (at 4–5 weeks postinjection) and animals were then
monitored for relapse until week 12. Figure 4b shows that tumors that relapsed in both the
control groups were significantly larger than relapsed tumors from the clones with reduced
expression of TNC. Therefore, tumors with high expression of TNC are more prone to relapse
following surgical resection than tumors with low expression of this protein.
To determine whether reduced TNC altered cell proliferation, which could be responsible for
the decrease in tumor growth of both the primary and relapsed tumors, we conducted
anchorage-dependent and -independent proliferation assays, and quantified PCNA-positive
cells in the tumor samples. No differences in rates of anchorage-dependent proliferation were
found between control cells and shTNC-1 or shTNC-3 clones as analysed by MTT assays of
cells attached to the flask (results not shown). However, anchorage-independent cell growth
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was significantly reduced (P < 0.01) in cell clones with reduced expression of TNC compared
to control cells (Figures 4c and d).
We also analysed the number of proliferating cells (PCNA-positive), and the total number of
tumor cells, in sections of primary tumors (Figures 4e and f). The number of PCNA-positive
cells was significantly reduced in shTNC-1 (P < 0.05) and shTNC-3 (P < 0.01) tumors
compared to controls. The number of PCNA-positive cells was reduced by 46.7% in shTNC-3
tumors, as compared to shCtrl tumors. In addition, the total number of tumor cells per reference
area was found to be reduced in shTNC-1 tumors compared to control tumors (P < 0.05) but
did not reach the significance for the shTNC-3 tumors: 388 ± 33 for control MDA-MB-435,
348.2 ± 16 for shCtrl, 285 ± 14 for shTNC-1 and 313 ± 13 for shTNC-3.
To determine whether downregulation of TNC was impairing tumor angiogenesis, we
quantified CD-31 levels by immunohistochemistry and image analysis, and Q-RT-PCR, in
primary tumors. No decrease in CD-31 mRNA or protein levels was seen in shTNC-1 or
shTNC-3 clones compared to MDA-MB-435 or shCtrl cells (results not shown). Therefore,
alterations in angiogenesis do not appear to be involved in TNC-dependent reduction of tumor
size.
The number of lung metastatic foci was quantified in mice 2 weeks after injection of 2 × 104
cells into the tail vein. At this time, lungs only showed microscopic metastatic foci (Figure 5a).
This time point was selected to avoid the difficulty in counting foci that become confluent at
later times in the TNC high-expressing MDA-MB-435 cells. Mice injected with shCtrl cells
had the highest number of metastatic foci (Figure 5b), correlating to their high TNC expression
(Figure 3d). The number of metastatic foci was significantly reduced when comparing the
shCtrl group with the shTNC-3 group (P < 0.05), and almost reached a significant difference
when compared with the shTNC-1 group (P = 0.05). Comparison between combined data from
both the control groups with combined data from shTNC groups showed a significant reduction
(P = 0.025) in the number of metastatic foci.
Discussion
A major component of the complex metastatic process involves the generation of new blood
vessels within the tumor through angiogenesis, where VEGF plays a key role (Ferrara, 1999).
We have demonstrated that the targeted overexpression of VEGF in the context of Myc
overexpression drastically alters the biologic behavior of mammary tumors leading to a high
rate of lung metastases. As predicted, Myc/VEGF tumors are highly angiogenic, with increased
vascularity and expression of angiogenic markers (VEGF, Flk-1, Flt-1, CD-31 and VE-
cadherin).
Earlier studies from our group and others have demonstrated that VEGF may also act as an
autocrine growth factor for breast tumor cells (Huh et al., 2005; Schoeffner et al., 2005). In
this regard, the observation that Myc/VEGF compound transgenic tumors had an increased
latency and decreased incidence, compared to tumors developed solely by targeted
overexpression of Myc, was unexpected. Although the mechanism for this paradoxical effect
remains unclear, the reduced tumor incidence and increased latency appear to correlate with a
reduction in Myc levels in the Myc/VEGF tumors compared to Myc tumors. As both the
transgenes operate off the MMTV promoter, it is possible that the transgenes compete for the
same transcription factors, thus reducing the level of Myc transcription. Alternatively, it may
be possible that VEGF overexpression inhibits transgene transcription or alters steady-state
levels of Myc, or indeed that VEGF overexpression renders the mammary epithelial cells to
be more refractory to the tumorigenic effects of Myc overexpression.
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Presumably many molecular alterations in the primary tumors identified through our gene
expression profiling studies occur through both direct and indirect effects of VEGF and are
potentially involved in the increased metastatic phenotype observed in Myc/VEGF tumors.
The molecular characterization of this Myc/VEGF model of metastases further credentials it
as a relevant system in which to understand metastatic progression. Many differences in gene
expression of ECM-related genes, such as collagens, proteases and adhesion proteins
(fibronectin, laminins, integrins and tenascin-C) were observed between Myc/VEGF and Myc.
Deregulation of ECM-related genes has also been reported as a key feature of metastatic
signatures in several other microarray studies (Ramaswamy et al., 2003; Eckhardt et al.,
2005; Minn et al., 2005; Gupta et al., 2007). Interestingly, it has been shown that VEGF requires
interactions with ECM components to exert a proliferative effect on endothelial cells (Miralem
et al., 2001).
The Myc/VEGF tumors exhibited a fivefold increase in type 1 collagen α-1 (Colla1) which
was also found to be one of the 17 signature genes in a microarray meta-analysis predictive of
metastasis (Ramaswamy et al., 2003). Colla1 was also identified as a gene associated with
high metastatic potential in MMTV-PyMT mammary mouse tumors (Qiu et al., 2004).
Laminins are a family of ECM proteins that are involved in adhesion and migration of a variety
of cells (Miyazaki, 2006). Of the many laminin isoforms, laminin-5 (α3β3γ2), upregulated in
the Myc/VEGF mammary tumors, is important for the acquisition of tumor cell invasive
properties (Giannelli and Antonaci, 2000; Yamamoto et al., 2001).
In order to utilize the array expression data generated from the mouse metastasis model as a
filter to identify genes whose deregulated expression is also altered in metastatic human BC,
we compared the dataseis from this study with a lung metastasis gene signature for human BC
(Minn et al., 2005). Five genes were similarly deregulated in the Myc/VEGF mouse tumor
metastatic signature and in the lung metastasis signature from primary human BC: TNC,
MMP-2, collagen-6-A1, mannosidase-α-1A and HLA-DPA1. Previous reports demonstrated
that TNC modulates tumor and endothelial cell migration (Zagzag et al., 2002; Chiquet-
Ehrismann and Chiquet, 2003), and is expressed in metastatic BC (Chiquet-Ehrismann and
Chiquet, 2003). Moreover, TNC upregulates MMP-9 cooperatively with transforming growth
factor-β (TGF-β), in mammary cancer cells (Kalembeyi et al., 2003). Therefore, we performed
functional assays to determine the role of TNC in tumor growth and metastasis. We demonstrate
that blockade of TNC strongly impairs cell migration, anchorage-independent cell proliferation
and tumor growth. In addition, down-regulation of TNC causes a significant reduction in the
ability of cancer cells to disseminate and grow in the lungs.
Knock down of TNC does not modify cell proliferation rates of attached cells in culture, but
does decrease the clonogenic potential of cells cultured under anchorage-independent
conditions in soft agar, and inhibits tumor cell proliferation in vivo. This suggests that the
effects of TNC on proliferation require cellular interaction with the ECM. Our data indicate
that reduced angiogenesis is not responsible for the decreased tumor size in shTNC tumors, as
CD-31 levels were similar between shTNC tumors and control tumors. In addition, tumor
recurrence following surgical removal is significantly more rapid in mice whose original
tumors expressed high levels of TNC compared to tumors with low TNC expression. This may
be due to a higher proliferative rate of remaining tumor cells following resection, or that cells
expressing TNC are more invasive and less amenable to resection.
Importantly, we observed that the number of lung metastases correlates to the level of TNC
expression in MDA-MB-435 and derivative cells. A significant (37.6%) decrease in the number
of metastatic nodules was found in the lungs of mice injected with shTNC expressing cells
compared to mice injected with the control cells. This is in contrast to a previous study in which
loss of TNC expression in MMTV-PyMT mice did not decrease either the primary tumor
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growth or the rate of lung metastasis. It is likely that PyMT activates other metastatic pathways
not dependent upon TNC (Talts et al., 1999). Indeed, our previous microarray analysis of
MMTV-PyMT primary tumors failed to find TNC as one of the metastatic signature genes in
this model (Qiu et al., 2004), suggesting that mechanisms of metastatic progression may depend
upon earlier oncogenic events and the concerted effects of multiple genes and epigenetic
phenomena. Thus, TNC may significantly contribute to metastatic progression in certain
contexts. Therefore, an approach targeting several genes involved in metastasis may be
necessary to reduce metastatic BC.
Materials and methods
Animals
MMTV-Myc mice, obtained from Charles Rivers Laboratory and MMTV-VEGF165 mice
(Schoeffner et al., 2005) were in the FVB/N background. Mouse genotypes were determined
by PCR from tail DNA using standard conditions (Jhappan et al., 1990). Animals were
observed weekly to evaluate tumor onset and growth and were treated in accordance with the
guidelines of the Animal Care and Use of Laboratory Animals (NIH Publication No. 86-23,
1985) under an approved animal protocol.
Real time RT-PCR, northern blot and microarray analyses
Five tumors from either Myc or Myc/VEGF transgenic animals were used to quantify mRNA
levels of VEGF, Flk-1/KDR, Flt-1, PECAM/CD-31, VE-cadherin and cyclophilin (internal
control) by real time RT-PCR as previously described (Shih et al., 2002). Northern blots were
conducted according to previous publications (Amundadottir et al., 1995). Comparative gene
expression profiles between five Myc and five Myc/VEGF primary tumors were assayed by
microarray analysis using the Incyte Genomics mouse GEM1 set of cDNA clones as previously
described (Calvo et al., 2002) (see Supplementary Methods).
Histology, immunohistochemistry and western blot
Tumors and lungs were processed for histology, or snap frozen for molecular assays. The
number and size of macrometastases (> 100 µm2) and micrometastases (< 100 µm2) were
quantified in whole sections of lungs. The following primary antibodies were used for immuno-
histochemistry: Anti-Fit-1 and anti-Flk-1 (Santa Cruz, Santa Cruz, CA, USA), anti-tenascin-
C (Millipore, Temecula, CA, USA), anti-CD-31 (Pharmingen, San Diego, CA, USA), anti-
laminin-5 (Santa Cruz) and anti-PCNA (Dako, Capenteria, CA, USA). Western blots were
performed using standard procedures (Calvo et al., 2002). Anti-tenascin-C antibody
(Chemicon), anti-c-Myc (Santa Cruz) and anti-β-actin (Sigma, St Louis, MO, USA) were used
at a 1:1500–1:2000 dilutions. Quantification of the MVD in CD-31-stained tumors was
conducted by image analysis (see Supplementary Methods).
Cell culture, proliferation assays and in vivo assays
Cell lines from transgenic mice were isolated and characterized following published protocols
(Pei et al., 2004). MDA-MB-435 cells were purchased from ATCC (Manassas, VA, USA).
Cells were cultured in RPMI 1640 with 10% fetal calf serum (FCS) medium. Proliferation
assays were performed using the MTT assay (Roche, Palo Alto, CA, USA) following the
manufacturer's protocol. For orthotopic assays, 106 cells were used, and for lung metastasis
experiments, 2 × 104 cells were injected in the tail vein (see Supplementary Methods).
Generation of shRNA constructs for TNC
A 19-nucleotide (CAGTTACAGAATTAAGTAT) targeting TNC was cloned into the
pMSCV-Δ3′LTR vector to generate pRS-TNC. A control-sequence vector (pRS-Ctrl),
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employing the sequence GTTCAGTGGTTCGTAGGGC (not present in the human or mouse
transcriptome) was constructed. Vectorcontaining MDA-MD-435 cells were selected with 2
mg/ml puromycin.
Migration and anchorage-independent clonogenic assay
Migration assays were conducted as previously described (Suyama et al., 2003). Briefly, cells
were grown until confluence and then, a p20 pipette tip was used to scratch the confluent cells.
Twenty-four hours later, cells were fixed, stained with crystal violet and analysed using Image
Analysis software. Six wells per condition were used. Soft agar assays using standard protocols
were performed to evaluate the clonogenic potential of MDA-MB-435 cells, and clones shCtrl,
shTNC-1 and shTNC-3. Data are shown as number of colonies per cm2 (see Supplementary
Methods).
Statistical analysis
Kruskal-Wallis test was used to determine significant differences between the treatment
groups. The Mann–Whitney U-test was used to compare pairs of groups when appropriate.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Morphology of primary Myc and Myc/VEGF mammary tumors. (a) Adenocarcinoma of a Myc
transgenic mouse. (b) Adenocarcinoma of a Myc/VEGF mouse. (c) Adenosquamous
(metaplastic) carcinoma of a Myc/VEGF mouse. Arrows indicate stratified squamous
epithelium with keratinization. (d) Large pulmonary metastasis (arrow) with central necrosis
(N). Metastasis surrounds a bronchus (B). (e) Immunostaining for CD-31 in a Myc tumor. (f)
Myc/VEGF tumor showing higher vascularization (anti-CD-31 staining) than Myc tumors.
(g) Comparison of the mean vascular density between Myc and Myc/VEGF tumors. ***P <
0.0004.
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Figure 2.
Changes in gene expression between Myc and Myc/VEGF tumors. (a) Microarray spots for
GLYCAM-1 after competitive hybridization of Myc/VEGF tumors with Myc tumors. Bars
represent fold-change increase in Myc/VEGF tumors compared to Myc tumors. (b) Microarray
spots and fold-change increase for fibronectin-1 (FN-1) in Myc/VEGF tumors, as compared
to Myc cancers. (c) CEACAM-2 is downregulated in bitransgenic tumors in comparison with
Myc malignant tissues. (d) Validation of the upregulation of TCN by western blot. (e) Myc
tumor stained for TNC. As seen by immunohistochemistry, TNC was mainly found in the
extracellular matrix (ECM) and, in a lesser extent, in tumor cells. (f) Myc/VEGF tumor stained
for TNC. Immunostaining for TNC is stronger in Myc/VEGF than in Myc tumors. (g) Myc
tumor stained for laminin-5. Staining is observed in tumor cells and in the ECM. (h) Myc/
VEGF tumor stained for laminin-5. A stronger staining was found for these types of tumors.
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Figure 3.
Migration assays. (a) Migration of M630 cells is impaired by TCN and Flk-1 signaling
blockade. (b) Quantification of migration inhibition in M630 cells. Treatment with an Flt-1
antagonist did not change cell migration. Treatment with an Flk-1 inhibitor results in a
significant reduction of migration (P < 0.01). Treatment with an anti-TNC blocking antibody
also causes significant inhibition of cell migration (P < 0.01). The combination treatment using
anti-TNC plus Flk-1 inhibitor produces the strongest inhibitory effect (P < 0.01). (c) Migration
assays in MDA-MB-435 cells and cell clones shCtrl, shTNC-1 and shTNC-3. Downregulation
of TNC in clones shTNC-1 and shTNC-3 reduces significantly (P < 0.05) cell migration when
compared to MDA-MB-435 cells and the control clone shCtrl. (d) Western blot analysis to
Calvo et al. Page 14
Oncogene. Author manuscript; available in PMC 2009 September 11.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
determine TNC protein expression in MDA-MB-435, shCtrl, shTNC-1 and shTNC-3 cells.
*P < 0.05; **P < 0.01.
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Figure 4.
Decrease in primary tumor growth and cell proliferation in MDA-MB-435 cells with a
downregulated expression of TNC. (a) Primary tumor volume is significantly lower (P < 0.05)
in shTNC clones than in controls. (b) Relapsed tumor volume is significantly lower (P < 0.05)
in cell clones lacking TCN. (c) Clonogenic assay in anchorage-independent conditions shows
a lower number of colonies in shTNC clones, compared to controls. (d) Quantification of the
number of colonies demonstrates that reduction in TNC levels results in lower clonogenic
potential (P < 0.01) than that found for controls. (e) Immunohistochemistry for PCNA shows
a decrease in PCNA-positive cells in shTNC tumors, compared to controls. (f) Quantification
of PCNA-positive cells in primary tumors demonstrates that MDA-MB-435 and shCtrl tumors
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have similar rate of proliferating cells, which is higher than that found for shTCN-1 and
shTNC-3 clones. *P < 0.05; **P < 0.01.
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Figure 5.
Downregulation of TNC in MDA-MB-435 cells reduces the number of lung metastatic foci.
(a) Metastatic nodule (arrow) in the lung of a mouse injected with shCtrl cells. (b)
Quantification of the number of lung metastatic foci. The average number of metastatic nudules
was lower in animals injected with shTNC-3 cell clones than in mice injected with shCtrl cells
(P < 0.05). No statistically significant differences were found when comparing data from
shTNC-1 and shTNC-3 cells with parental cells or when comparing data from shTNC-1 with
the shCtrl group (*P = 0.05 for the latter comparison).
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Table 1
Selected list of genes with a potential role in the acquisition of the metastatic phenotype found in Myc/VEGF tumors
Gene name/gene category Average ratio Gene function/gene expression in cancer
Associated with metastasis/invasion/adhesion
  CD-44 3.1±0.1 Upregulated in many metastatic tumors, including BC
  ECM-1 9.7±2.2 Angiogenesis and bone formation. Upregulated in
metastatic BC
  Metastasis-associated gene 1 (MTA-1) 2.0±0.4 Metastasis signature
  GLYCAM-1 15.8±2.7 Adhesion molecule. Upregulated in metastatic BC
  Fibronectin-1 6.8±1.4 Metastatic signature in many types of tumors,
including BC
  Laminin-5-γ-2 10.6±1.1 Metastatic signature in many types of tumors,
including BC
  Rho-related GTPases Cytoskeletal reorganization through actin interaction
    Rho-C 2.0±0.2 Metastatic signature in melanoma
    Rac-1 −2.0±0.6
    Rho-GDI-γ −1.8±0.1
    Rap −2.0±0.1
    Pak-1 1.7±0.3
  Integrin α3 2.6±0.2 Metastatic signature for some types of tumors
  P-cadherin 2.0±0.5 Upregulated in BC in relation to ER loss and
malignancy
  CEACAM-1 −3.3±0.1 Downregulated in several types of tumors including BC
  CEACAM-2 −2.5±0.2 Unknown expression in tumors
  Tenascin-C 5.5±2.3 Cell-ECM adhesion. Upregulated in many types of
tumors
ECM
  Procollagen I, α-1 5.0±2.1 Fibers of connective tissue. Metastatic signature
  Procollagen III, α-1 4.8±1.7 Fibers of connective tissue
  Procollagen V, α-2 6.5±1.8 Fibers of connective tissue
  Procollagen VI, α-1 3.2±1.0 Fibers of connective tissue
  Procollagen XIV, α-1 3.2±1.0 Fibers of connective tissue
Angiogenesis
  Hypoxia-induced gene-1 2.4±0.0 Activates expression of pro-angiogenic factors
  Neuropilin 2.1±0.3 VEGF receptor. Promotion of tumor angiogenesis
Proteinases
  MMP-2 5.2±1.4 Promotes ECM degradation and activation of growth
factors. Upregulated in many types of carcinomas,
including BC
  MMP-23 2.2±0.5 Unknown substrate and function
  Cathepsin-L 3.0±1.0 Promotes ECM degradation. Upregulated in BC
  Cathepsin-C 2.0±0.1 Promotes ECM degradation. Unknown status in cancer
  ADAMs Family of proteins which interact with integrins,
implicated in proteolytic cleavage of cell surface
molecules
    ADAM-8 3.7±0.7
    ADAM-9 2.0±0.2
    ADAM-12 3.4±1.2
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Gene name/gene category Average ratio Gene function/gene expression in cancer
    ADAM-19 2.2±0.6
  Cystatin-C 2.7±0.1 Protease inhibitor
  Cystatin-B 3.8±0.4 Protease inhibitor
Cytoskeleton
  Keratins Family of proteins related to cytoskeleton
    Krt1-19 9.3±0.7
    Krt2-6a 23.5±2.9
    Krt1-13 7.1±1.4
    Krt2-4 2.7±0.1
  Dystonin 3.8±0.7 Interacts with actin and microtubules
Cell signaling
  AXL-receptor tyrosine kinase 4.6±1.0 Involved in cell signaling related to cell adhesion
  Myristoylated alanine-rich C-kinase
substrate
4.7±0.3 Participates in cytoskeletal remodeling
Growth factors
  TGF-β induced 68 kDa 4.8±2.4 Cell growth of stromal components. Promotion of
tumor angiogenesis. Interaction with ECM components
  BMP-1 3.3±0.8 Bone formation. Promotion of angiogenesis
Cell cycle/transcription factors
  c-Myc −10.0±0.1 Transcription factor involved in cell cycle regulation
and
apoptosis. Overexpressed in a high percentage of BC
  Myb −2.9±0.4 Transcription factor involved in cell cycle regulation,
overexpressed in several types of tumors including
some CB
  Cyclin B −2.5±0.8 Cell cycle regulator. It binds to cdc2
  Cdk-1 −2±0.1 Cell cycle regulator. It binds to cyclin B
  Cyclin D1 2.1±0.2 Increased expression in BC, especially in metastasis.
Collaboration with Rho GTPases in cell migration
signaling
  Cyclin G 3.4±0.2 Cell cycle regulator at the S, G2/M checkpoint
Abbreviations: BC, breast cancer; BMP, bone morphogenetic protein; ECM, extracellular matrix; MMP, matrix metalloprotease; TGF, transforming
growth factor-β; VEGF, vascular endothelial growth factor.
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